ArticleApplied biochemistry and biotechnology2025
Targeting TXN1 Induces G2M Phase Arrest and Apoptosis of Glioma Cells Through P38 MAPK Pathway.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Glioma is the most common and aggressive primary adult brain tumor. Furthermore, the prognosis for glioma patients following chemoradiotherapy is unfavourable due to the inherent anti-apoptotic characteristics of glioma cells. Thus, the treatment of gliomas remains a challenge. Our aim was to define the molecular mechanisms underlying the effects of TXN1 on the anti-apoptotic ability and proliferation of glioma cells. The relationship between TXN1 expression and glioma patients was initially predicted using bioinformatics methods and then verified through clinical glioma tissue Results showed that the expression of TXN1 increases with the malignant degree of glioma, leading to a worse prognosis for patients.Then glioma cells were treated with lentivirus to be stable cell lines with suppressed TXN1 expression. MTT, flow cytometry, immunofluorescence, western blot and qRT-PCR were used to analyse changes in glioma proliferation, cell cycle, apoptosis and the expressioin of the P38 MAPK signaling pathway. Moreover,the expression levels of related proteins in the transplanted tumor tissues of nude mice were investigated by immunohistochemistry. Reducing TXN1 expression caused glioma cell cycle in G2/M phase, increased cell apoptosis rate and mitochondrial membrane damage. Furthermore, this was correlated with activity of the P38 MAPK pathway. Reduction of TXN1 expression can activate the P38 MAPK pathway to cause glioma cell cycle arrest and induce mitochondrial apoptosis. This study revealed for the first time that inhibition of TXN1 can destroy the apoptotic resistance mechanism of glioma by activating ASK1/P38 MAPK axis, resulting in G2/M phase arrest of glioma cells, inhibiting the proliferation of glioma cells, and promoting apoptosis of glioma cells in malignant gliomas. Combining TXN1 inhibitors with radiotherapy and chemotherapy is expected to significantly improve the clinical prognosis of glioma patients.
Indexed as
Identifiers
40833712What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.